GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Corline Biomedical CLBIO.ST · SEK

Health Care · Nasdaq Stockholm · 🇸🇪 Sweden

Compare

12.80

-1.16%

Close of 9 Nov 2026, in SEK

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Corline Biomedical

Its shares trade on Nasdaq Stockholm under the ticker CLBIO.ST. It has been listed since 3 June 2015. In the fiscal year to 31 December 2025, it reported revenue of SEK 7.7m and a net loss of SEK 14.7m. At that date it held total assets of SEK 98.6m and shareholders' equity of SEK 93.8m.

Corline Biomedical AB engages in the research, development, and commercialization of heparin based solutions. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2015-06-03. The company develops, manufactures and markets heparin-based solutions to improve kidney transplantation, cell therapies and applications in regenerative medicine.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
3 Jun 2015
Employees
8

Leadership

Pay as last reported

  • Gunilla Anders Ekström, MD, PhDIndependent Non-Executive Director, since 2017
  • Lars Fredrik SunnanväderNon-Executive Director, since 2005
  • Lars Henrik Nittmar, PhDChief Executive Officer, since 2008
  • Gunnar Tufveson, MDChief Medical Officer, since 2018
  • Magnus Nilsson, MDDeputy Director, since 2020
  • Fredrik Carlsson, PhDManager-Research
  • Jessica MagnussonManager-Regulatory Affairs & Quality, since 2010
  • Lars Adam Holger Dahlberg, MBAChairman, since 2005
  • Henrik Krook, PhD, EMBANon-Executive Director, since 2018
  • Kerstin Valinder-StrinnholmIndependent Non-Executive Director, since 2015

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Corline Biomedical AB focuses on heparin-based solutions for kidney transplantation and regenerative medicine.
  • The company has a small team of 8 employees dedicated to pharmaceutical research and development.
  • Corline Biomedical AB's IPO in 2015 established a strong market presence in the Health Care sector.

Weaknesses

  • Corline Biomedical AB operates with only 8 employees, limiting its operational capacity.
  • The company's heparin-based solutions are specific to niche medical applications.
  • Corline Biomedical AB has no significant product diversification beyond heparin-based therapies.

Opportunities

  • Expanding heparin-based solutions into cell therapies and regenerative medicine markets.
  • Corline Biomedical AB can leverage its Uppsala location for European healthcare partnerships.
  • Growing demand for kidney transplantation solutions presents new market opportunities.

Threats

  • Competition from larger pharmaceutical companies in the heparin market.
  • Regulatory challenges in the Health Care sector could impact product approvals.
  • Dependence on heparin-based solutions may limit growth in broader medical markets.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.